Clinical Trial Update: Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of cerdulatinib gel 0.37% in adults with vitiligo has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Cerdulatinib gel 0.37% (cerdulatinib)

Snippet

Sponsor: Dermavant Sciences GmbH | Conditions: Vitiligo | Phase 2 | Status: COMPLETED